Preradiation Chemotherapy with VM-26 and CCNU in Patients with Glioblastoma Multiforme

Jemal A. , Murray T. , Samuels A. , Ghafoor A. , Ward E. , Thun M.J. : Cancer statistics, 2003. CA Cancer J Clin, 53: 5–26, 2003.

Eusko Jaurlaritza/Gobierno Vasco. In: La incidencia del cáncer en el País Vasco (1987-1991), Servicio Central de Publicaciones del Gobierno Vasco, 136-137, Vitoria-Gasteiz, 1997.

Prados M.D. , Berger M.S. , Wilson C.B. : Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin, 48: 331–360, 1998.

Selby R. : The surgical treatment of cerebral glioblastoma multiforme: An historical review. J Neurooncol, 18: 175–182, 1994.

Benesh M. , Urban C. : Influence of surgical resection on adjuvant therapy and outcome [letter]. J Clin Oncol, 16: 389–390, 1998.

Kristiansen K. , Hagen S. , Kollevold T. , Torvik A. , Holme I. , Nesbakken R. , Hatlevoll R. , Lindgren M. , Brun A. , Lindgren S. , Notter G. , Andersen A.P. , Eigen K. : Combined modality therapy of operated astrocytomas grade III and IV — confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47: 649–652, 1981.

Curran W.J. , Scott C.B. , Horton J. , Nelson J.S. , Weinstein A.S. , Fischbach A.J. , Chang C.H. , Rotman M. , Asbell S.O. , Krisch R.E. : Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85: 704–710, 1993.

Edwards M.S. , Levin V.A. , Wilson C.B. : Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep, 64: 1179–1205, 1980.

Kornblith P.L. , Walker M. : Chemotherapy for malignant gliomas. J Neurosurg, 68: 1–17, 1988.

Hosli P. , Sappino A.P. , de Tribolet N. , Dietrich P.Y. : Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol, 9: 589–600, 1998.

Kessinger A. , Lemon H.M. , Foley J.F. : VM-26 as a second drug in the treatment of malignant gliomas. Cancer Treat Rep, 63: 511–512, 1979.

McVie J.G. : Teniposide (VM-26) in brain tumors. Semin Oncol, 19(2 Suppl 6): 85–88, 1992.

Fine H.A. , Dear K.B.G. , Loeffler J.S. , Black P.M. , Canellos G.P. : Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71: 2585–2597, 1993.

Glioma meta-analysis trialists (GMT) group: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359: 1011–1018, 2002.

Lassen U. , Kristjansen P.E. , Wagner A. , Kosteljanetz M. , Poulsen H.S. : Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol, 43: 161–166, 1999.

Gilbert M.R. , Friedman H.S. , Kuttessh J.F. , Prados M.D. , Olson J.J. , Reaman G.H. , Zaknoen S.L. : A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncology, 4: 261–267, 2002.

Grossman S.A. , Wharam M. , Sheider V. , Keinberg L. , Zeltzman M. , Yue N. , Piantadosi S. : Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol, 15: 2596–2603, 1997.

Grossman S.A. , O'Neill A. , Grunnet M. , Mehta M. , Pearlman J.L. , Wagner H. , Gilbert M. , Newton H.B. , Hellman R. : Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol, 21: 1485–1491; 2003.

Sheline G.E. , Wara W.M. , Smith V. : Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys, 6: 1215–1228, 1980.

MacDonald D.R. , Cascino T.L. , Schold S.C. , Cairncross J.G. : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8: 1277–1280, 1990.

Brandes A.A. : State-of-the-art treatment of high-grade brain tumors. Semin Oncol, 30(Suppl 19): 4–9, 2003.

Greig N.H. : Optimizing drug delivery to brain tumors. Cancer Treat Rev, 14: 1–28, 1987.

Stewart P.A. , Farrell C.L. , Del Maestro R.F. : The effect of cellular microenvironment on vessels in the brain. Part 1: Vessel structure in tumor, peritumour and brain from humans with malignant glioma. Int J Radiat Biol, 60: 125–130, 1991.

Hasegawa H. , Ushio Y. , Hayakawa T. , Yamada K. , Mogami H. : Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg, 59: 304–310, 1983.

Walker M.D. , Green S.B. , Byar D.P. , Alexander E. , Batzdorf U. , Brooks W.H. , Hunt W.E. , MacCarty C.S. , Mahaley M.S. Jr. , Mealey J. Jr. , Owens G. , Ransohoff J 2nd , Robertson J.T. , Shapiro W.R. , Smith K.R. Jr. , Wilson C.B. , Strike T.A. : Randomized comparisons of rediotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med, 303: 1323–1329, 1980.

Green S.B. , Byar D.P. , Walker M.D. , Pistenmaa D.A. , Alexander E. , Batzdorf U. , Brooks W.H. , Hunt W.E. , Mealey J. Jr. , Odom G.L. , Paoletti P. , Ransohoff J 2nd , Robertson J.T. , Selker R.G. , Shapiro W.R. , Smith K.R. Jr. , Wilson C.B. , Strike T.A. : Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep, 67: 121–132, 1983.

Chang C.H. , Horton H. , Schoenfeld D. , Salazer O. , Perez-Tamayo R. , Kramer S. , Weinstein A. , Nelson J.S. , Tsukada Y. : Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer, 52: 997–1007, 1983.

Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol, 21: 3276–3284, 2003.

Dazzi C. , Cariello A. , Giannini M. , Del Luca M. , Giovanis P. , Fiorentini G. , Leoni M. , Rosti G. , Turci D. , Tienghi A. , Vertagen B. , Zumaglini F. , De Giorgi U. , Marangolo M. : A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study. Anticancer Res, 20: 515–518, 2000.

Brandes A.A. , Ermani M. , Basso U. , Paris M.K. , Lumachi F. , Berti F. , Amista P. , Gardiman M. , Iuzzolino P. , Turazzi S. , Monfardini S. : Temozolomide in patients with glioblastoma at second relapse after first-line nitrosourea-procarbazine failure: a phase II study. Oncology, 63: 38–41, 2002.

Chinot O. , Barrie M. , Couprie C. , Dufour H. , Figarella D. , Muracciole X. , Braguer D. , Hoang-Huan K. , Peragut J-C , Grisoli F. : Preradiation combination of temozolomide (TMZ) and BCNU as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM). Proc ASCO, 22: 108 (abstr 431), 2003.

Stupp R. , Dietrich P.Y. , Kraljevic S.O. , Pica A. , Maillard I. , Maeder P. , Meuli R. , Janzer R. , Pizzolato G. , Miralbell R. , Porchet F. , Regli L. , de Tribolet N. , Mirimanoff R.O. , Leyvraz S. : Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20: 1375–1382, 2002.

Wood J.R. , Green S.B. , Shapiro W.R. : The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol, 6: 338–343, 1988.

Deutsch M. , Green S.B. , Strike T.A. , Burger T.A. , Robertson J.T. , Selker R.G. , Shapiro W.R. , Mealey J. Jr. , Ransohoff J 2nd , Paoletti P. : Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys, 16: 1389–1396, 1989.